Y-mabs reports fourth quarter and full year 2023 financial results and recent corporate developments

New york, feb. 29, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the quarter and full year ended december 31, 2023.
YMAB Ratings Summary
YMAB Quant Ranking